Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.

April 12
Pacira Pharmaceuticals, Inc. Prices Public Offering of Common Stock

CircuLite to Provide New Information on Synergy in Three Presentations at ISHLT Annual Meeting

Advaxis Awarded Best Therapeutic Vaccine

April 11
Proteonomix Announces Termination of Contract with the University of Miami

April 10
Advaxis Announces Presentations at World Vaccine Congress 2012

Boiron USA Selects & Implements Cegedim Relationship Management’s Cloud-Based Solutions Mobile Intelligence for iPad and Xtelligence Analytics Suite

April 9
Proteonomix Updates Progress on Multiple Programs

April 5
Advaxis Announces Collaboration with the Karolinska Institutet

April 4
Personalized Medicine and Combination Potential of Cyclacel’s Sapacitabine Highlighted at AACR

New Leadership Team for Ipsen Operations in North America to Drive Growth in Neurology and Endocrinology

BASF and Catalent Join Forces to Solve Bioavailability Challenges

Bristol-Myers Squibb to Present New Data Demonstrating Company’s Commitment to Research and Development in Liver Disease at The International Liver Congress / European Association for the Study of the Liver (EASL) Annual Meeting

April 3
MPI Research and Edge Therapeutics Partner to Advance Development of Life-Saving Therapies after Brain Hemorrhage Drugs Utilize Novel, Site-Specific and Sustained Release-Microparticle Technology Platform

Unigene’s Proprietary Oral Peptide Delivery Platform Is Further Validated with Cara Therapeutics’ Successful Completion of Its Phase 1 Study Using Unigene’s Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845

Laureate Biopharma Names James D. Utterback to Board of Directors

Immunomedics Develops Novel Agents Targeting Renal Cell Carcinoma

April 2
VaxInnate Names Wayne Pisano as Its New CEO

Efficacy and Safety Data for ZOSTAVAX (Zoster Vaccine Live), Merck’s Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases

Unigene Appoints Jack Wyszomierski to Its Board of Directors

Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer

Cyclacel’s Novel Polo-Like Kinase 1 (Plk1) Inhibitors Highlighted at AACR

Immunomedics Develops Bispecific Hexavalent Antibodies for Diverse Epithelial Cancers

Bristol-Myers Squibb to Announce Results for First Quarter 2012 on April 26

March 30
QPharma Executive Promoted to Chief Information Officer

March 29
Oticon, Inc. Introduces Invisible Hearing Device for People Who Want the Ultimate in Discretion

March 28
Antares Pharma to Present at the 11th Annual Needham Healthcare Conference

Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer’s Disease

Advaxis Announces Abstracts Accepted for Poster Presentation at AACR Annual Meeting 2012

Alliance Life Sciences Implements MemberMATCH Solution with New Functionality for Top-Five Pharma Client, Streamlines Group Purchasing Organization Membership Confirmation Process

Merck Appoints Michael J. Holston as Chief Ethics and Compliance Officer

Merck Provides Update on IMPROVE-IT Trial

Proteonomix, Inc. Updates Progress of Proteoderm Subsidiary

Aegerion Pharmaceuticals to Present at the Needham Healthcare Conference

March 27
Durata Therapeutics Appoints John P. Shannon as Chief Commercial Officer with Responsibility to Build Commercial Team

Merck to Hold First-Quarter 2012 Sales and Earnings Conference Call on April 27

Laureate Biopharma Appoints Lisa Cozza as Vice President, Business Development

NPS Pharmaceuticals to Present at Needham Healthcare Conference

Lexicon Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference

March 26
Immunomedics to Report Progress with Novel DNL Agents Targeting Solid Tumors at Cancer Conference

Cyclacel to Announce Year-End and Fourth Quarter 2011 Financial Results and Multiple Presentations at the Upcoming AACR Conference

March 24
In TRA-2P Study, Adding Merck’s Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events

March 22
Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses on Certain Intellectual Property

Supreme Court Denies Apotex’s Petition for a Writ of Certiorari

March 21
Data on ELIQUIS (apixaban) for the Prevention of Stroke in Atrial Fibrillation to Be Presented at American College of Cardiology’s 61st Annual Scientific Session

March 20
Advaxis Continues Collaboration with Former NCI Vaccines Chief in New Position as Director of the Georgia Health Sciences University Cancer Center

SAFE-BioPharma Named Computerworld Laureate for IT Use Benefiting Society

NovaDel Reports Unaudited Financial Results for Fourth Quarter and Year Ended December 31, 2011

Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote on Investigational Medicine Ridaforolimus for the Treatment of Metastatic Soft-Tissue or Bone Sarcomas

Merck and Safe Water Network Launch Initiative to Improve Water Access and Help Reduce the Impact of Water-Borne Disease in India

Aegerion Pharmaceuticals Announces EMA Acceptance for Review of Marketing Authorization Application for Lomitapide

FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome